Takeda Canada Inc. ("Takeda") announced that REVESTIVE® (teduglutide for injection) will now be reimbursed by BC PharmaCare ...
Johnson & Johnson today announced results from the Phase 3 FUZION study evaluating TREMFYA® (guselkumab) in adults with active perianal fistulizing Crohn's disease (CD). At Week 24, TREMFYA ...
Johnson & Johnson today announced Phase 2b data from two studies evaluating JNJ-4804, an investigational co-antibody therapy targeting both interleukin-23 (IL-23) and tumor necrosis factor-alpha (TNF- ...
ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase ...
In the rapidly evolving field of immunomodulation, few compounds have garnered as much interest for their precision as the ...
Tacoma Rainiers The Rainiers dropped the series 4-2 this week, unfortunately unable to land the knockout punch in several ...
Addressing offshore construction challenges requires a multidisciplinary approach, combining pipeline engineering, ...
Objectives Smoking is recognised as one of the strongest environmental risk factors for the development of rheumatoid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results